No Data
No Data
Innate Pharma: Clarification Regarding SAR443579 Designation
Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) ("Innate" or the "Company") today announced that in an abstract published on 14 May 2024 for the European Hematology Association 2024 Congress on SAR443579/IPH6101, submitted by Sanofi, it was mentioned that the molecule received breakthrough designation. This is an error. The molecule has US FDA Fast Track Designation, as communicated before in June 2023.
Innate Pharma Unveils Promising Cancer Therapies at EHA
Innate Pharma's Four Abstracts With Innate's Drug Candidates Accepted For The European Association Of Hematology 2024 Congress
Two abstracts on SAR443579 (IPH6101), ANKET platform lead asset, a trifunctional anti-CD123 NKp46xCD16 NK cell engager under development by partner Sanofi in blood cancerTwo abstracts on IPH6501, Inna
Innate Pharma Highlights Abstracts Selected for EHA 2024 Congress
Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) ("Innate" or the "Company") announced today that four abstracts with Innate's drug candidates have been accepted for the European Association of Hematology (EHA) 2024 Congress, taking place June 13-16, 2024 in Madrid, Spain.
Analysts Have Conflicting Sentiments on These Healthcare Companies: Curis (CRIS), Health Catalyst (HCAT) and Innate Pharma SA (OtherIPHYF)
Earnings Call Summary | Innate Pharma(IPHA.US) Q1 2024 Earnings Conference
The following is a summary of the Innate Pharma S.A. (IPHA) Q1 2024 Earnings Call Transcript:Financial Performance:Innate Pharma has a firm cash status with about EUR115 million in cash as of the end
No Data